There isn't a blood marker for disorders affecting the brain
For generations, the brain has remained medicine's most guarded interior — shielded by biology, accessible only through inference and conversation. Researchers at Johns Hopkins have now found that the brain may already be speaking outward, releasing genetic whispers into the bloodstream that carry the signature of its inner states. By learning to read these molecular messages in a routine blood draw, scientists have opened a quiet but consequential door: the possibility of detecting psychiatric illness — including postpartum depression — before it reaches its most devastating expression.
- Millions of people living with psychiatric disorders have no biological test to confirm their diagnosis — medicine has long relied on conversation alone, leaving disease invisible to the lab.
- The brain's isolation behind its protective barrier has made objective measurement feel nearly impossible, while conditions like postpartum depression and schizophrenia continue to go undetected until crisis arrives.
- Johns Hopkins researchers discovered that tiny fatty particles drifting through the bloodstream carry brain-specific genetic material — effectively a molecular broadcast from the brain that was always transmitting, but never decoded.
- Thirteen distinct genetic markers tied to postpartum depression were identified in blood samples, with overlapping signals pointing toward schizophrenia, epilepsy, mood disorders, and substance abuse.
- The team is now moving toward autism research and, ultimately, a clinical blood test that could flag psychiatric emergencies — including suicide risk — early enough for intervention to matter.
A team at Johns Hopkins Children's Center has found a way to detect the brain's activity through a simple blood draw — a discovery that could reshape how psychiatry approaches diagnosis. The key lies in extracellular vesicles, tiny fatty particles that circulate through the bloodstream carrying genetic material shed by organs throughout the body, including the brain. Published in Molecular Psychiatry, the research suggests the brain has always been sending signals outward — medicine simply hadn't learned to read them.
The team began with a proof of concept rooted in pregnancy. The placenta releases its own vesicles into maternal blood, and the researchers identified 26 genetic fragments — mRNAs — that appear only during pregnancy and disappear after birth. Tissue-specific signals, it turned out, could be reliably detected in circulating blood. From there, they grew miniature brain-like structures from stem cells in the lab, collected the vesicles those tissues released, and confirmed that the genetic material inside reflected what was happening within the brain tissue itself.
Cross-referencing large human genetic databases, the team identified mRNAs specific to the brain and mapped the pathways they regulate. What emerged was striking: many of those pathways were already associated with psychiatric and neurological disease — mood disorders, schizophrenia, epilepsy, and substance abuse. The signals in the blood were not random noise. They appeared to carry meaningful information about brain health.
Focusing on postpartum depression — a condition diagnosed today through clinical interviews alone — the researchers identified 13 brain-specific mRNAs in blood associated with the disorder. The long-term ambition is a routine blood test capable of detecting early warning signs of psychiatric crisis, including suicidal behavior, before a patient reaches a breaking point. The team plans to extend the work to autism next, though they acknowledge an important caveat: the study drew only from female samples, meaning the depression markers may be specific to the postpartum context. The science is promising and preliminary in equal measure — its true weight will only be known when it moves from the lab into the lives of patients.
A team at Johns Hopkins Children's Center has found a way to read the brain's activity from a simple blood draw. The discovery, published in January in Molecular Psychiatry, hinges on a biological messenger system that most people have never heard of: tiny fatty sacs called extracellular vesicles that float through the bloodstream carrying genetic material released by every organ in the body, including the brain.
The researchers were chasing a specific problem. Postpartum depression affects a significant number of women after childbirth, yet doctors have no blood test to diagnose it. They rely instead on clinical interviews—asking patients how they feel. The same is true for schizophrenia, epilepsy, autism, and most other brain disorders. There is no biological marker, no objective measure a lab can run. The brain sits behind the blood-brain barrier, largely inaccessible without invasive procedures. But what if the brain was already sending signals out into the bloodstream, and no one had learned to read them yet?
The Johns Hopkins team started with the placenta. During pregnancy, the placenta releases extracellular vesicles into maternal blood. The researchers identified 26 pieces of genetic material—mRNAs—that appear in those vesicles only while a woman is pregnant and vanish after birth. This was the proof of concept: tissue-specific genetic signatures can be detected in circulating blood. The signal is there. You just have to know what to look for.
Next, they grew human brain tissue in the lab from stem cells, creating what scientists call brain organoids—miniature brain-like structures. They collected the extracellular vesicles released by these tissues and examined the mRNA inside. What they found was striking: the genetic material in the vesicles reflected the activity happening inside the brain tissue itself. The correlation was not perfect—cellular mRNA levels and vesicle mRNA levels are not identical—but they tracked together closely enough that changes in the brain could be inferred from changes in the blood.
Using two large databases of human genetic information, the team identified which mRNAs are specific to the brain and which genes they regulate. When they analyzed the genetic pathways controlled by these brain-specific mRNAs, they discovered something important: many of them were already known to be involved in psychiatric and neurological disease. Genes linked to mood disorders, schizophrenia, epilepsy, and substance abuse showed up repeatedly. The researchers had found not just any genetic signals in the blood, but signals that seemed to matter for brain health.
Then they focused on postpartum depression. They identified 13 brain-specific mRNAs in blood that were associated with the condition. Thirteen biological markers that could, in theory, be measured in a routine blood test. Lena Smirnova, a researcher at the Johns Hopkins Bloomberg School of Public Health and co-author of the study, noted the significance: there is currently no blood marker for any disorder affecting the brain. This work suggests a path forward.
The long-term vision is straightforward but profound. A simple blood test could detect early warning signs of psychiatric crisis—including suicidal behavior—before a patient reaches a breaking point. Doctors could identify people at risk of a psychiatric episode and intervene early, possibly preventing tragedy. The team plans to extend this work to autism spectrum disorder next. But they are careful about one limitation: the study used samples only from women, so the depression markers they identified may be specific to postpartum depression rather than depression more broadly. The work is promising, but it is also preliminary. The real test will come when these findings move from the lab into clinical practice.
Citações Notáveis
We only detected placenta-specific extracellular vesicles during pregnancy, not after birth. This proved we can detect vesicles coming from a specific tissue or organ.— Sarven Sabunciyan, assistant professor of pediatrics at Johns Hopkins University School of Medicine
Right now, there isn't a blood marker for disorders affecting the brain. These conditions are diagnosed by clinical interviews between patients and providers.— Lena Smirnova, assistant professor at Johns Hopkins Bloomberg School of Public Health
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that you can detect these mRNAs in blood if you can't directly access the brain anyway?
Because right now, psychiatrists diagnose by talking to patients. There's no objective measure. If a woman says she's depressed after giving birth, a doctor has to decide whether to believe her, whether it's severe enough to treat, whether she's at risk. A blood test removes that guesswork. It's biological fact.
But you said the mRNA levels in the blood don't perfectly match what's happening in the brain tissue.
They don't. But they correlate. Think of it like a shadow on a wall—it's not the object itself, but it tells you something true about the object's shape and movement. Close enough to be useful.
The study only used women. Does that mean this won't work for men with depression?
It means we don't know yet. The researchers were specifically studying postpartum depression, which is a female experience. Whether these same mRNA markers show up in men with major depression is an open question. That's honest science—naming what you don't know.
What would early detection actually change? If you find someone at risk, what happens next?
That's the hope, anyway—intervention before crisis. If you can identify someone heading toward a psychiatric emergency, including suicidal behavior, you can get them support, medication, hospitalization if needed. You're trying to prevent the worst outcome before it happens.
How far away is this from being a real test a doctor could order?
Still years away. This is proof of concept. They've shown the signal exists and can be measured. Now it needs to be validated in larger groups of people, refined, turned into an actual clinical test. The science is real, but the application is still in development.